Patients with suspected inflammatory bowel disease (IBD) could benefit from better testing protocols that would reduce the need and lengthy wait for potentially unnecessary colonoscopies, a new study has found.
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product | Psychedelic Invest
Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of
May 10, 2024